NCT01133275View on ClinicalTrials.gov

Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 28, 2010

Primary Completion Date

January 31, 2015

Study Completion Date

November 21, 2019

Conditions
Myelodysplastic SyndromeMDS
Interventions
DRUG

Prednisone

Prednisone therapy for 6 cycles (24 weeks).

DRUG

Lenalidomide

Lenalidomide therapy for 6 cycles (24 weeks).

Trial Locations (2)

32610

University of Florida Shands Cancer Center, Gainesville

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER